Oxford BioDynamics is extremely proud to have received the Queen’s Award for Enterprise in Innovation.
Spun out of the University of Oxford in 2007, Oxford BioDynamics is a biotechnology company with a proprietary discovery platform called EpiSwitch™, which identifies and analyses biomarkers. These biomarkers can be used to diagnose diseases, predict disease progression, and help identify which patients will respond to specific drugs – delivering personalised medicine.
This award recognises Oxford BioDynamics’ outstanding achievements in scientific innovation and commercial success with EpiSwitch™, highlighting the company’s dedication to discover real-world solutions to otherwise unmet medical needs.
DNA, a person’s hereditary material, is packaged into chromosomes. EpiSwitch™ looks at changes that occur in the way chromosomes are folded, so called ‘Chromosome Conformation Signatures’ (CCSs). CCSs are a type of epigenetic biomarker based on the latest advances in the regulatory genome architecture and its link to clinical outcomes. Epigenetic markers are features that are on top of, or in addition to, the traditional genetic controls. With this highly innovative technology, Oxford BioDynamics has already completed studies into the potential detection and early diagnosis of life-changing diseases including cancer, ALS and Huntington’s disease.
For the wider pharmaceutical industry, the development of this platform can now reduce risk, cost and time to market for drug development; gain significant insight into disease mechanisms, and personalise therapeutic treatments.
Over the past year, Oxford BioDynamics has made significant commercial and operational advances, including strengthening its global IP portfolio; partnering with world-renowned biotechnology, pharmaceutical and academic institutions. It has entered into multiple research and development projects for commercial customers in diverse fields including immuno-oncology, fibrosis and thyroid cancer.
Christian Hoyer Millar, CEO of Oxford BioDynamics, says: “Our business is extremely proud to have received the Queen’s Award for Enterprise. It comes at an exciting time for the company as we continue to expand into new geographies, increase our commercial capacity and work to build a strong and reliable platform for the considerable benefit of patients worldwide.”